FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95

作者：Laura, Nelson；Hayley D, McKeen；Andrea, Marshall；Laoighse, Mulrane；Jane, Starczynski；Sarah J, Storr；Fiona, Lanigan；Christopher, Byrne；Ken, Arthur；Shauna, Hegarty；Ahlam Abdunnabi, Ali；Fiona, Furlong；Helen O, McCarthy；Ian O, Ellis；Andrew R, Green；Emad, Rakha；Leonie, Young；Ian, Kunkler；Jeremy, Thomas；Wilma, Jack；David, Cameron；Karin, Jirstr?m；Anita, Yakkundi；Lana, McClements；Stewart G, Martin；William M, Gallagher；Janet, Dunn；John, Bartlett；Darran, O'Connor；Tracy, Robson

来源：Oncotarget 2015 年 6卷 14期